-+ 0.00%
-+ 0.00%
-+ 0.00%

Grace Therapeutics FY26 net loss narrows 18.55% to $7.79 million

PUBT·06/18/2026 11:32:59
Listen to the news
Grace Therapeutics FY26 net loss narrows 18.55% to $7.79 million
  • Grace Therapeutics posted a fiscal 2026 net loss of USD 7.79 million, narrowing from the prior year; loss per share improved to USD 0.47.
  • Research and development expense fell to USD 2.41 million from USD 9.51 million, while general and administrative expense rose to USD 8.67 million.
  • Cash and cash equivalents ended March 31, 2026 at USD 16.98 million, down from USD 22.13 million a year earlier.
  • The FDA issued a complete response letter for GTx-104, citing CMC and non-clinical items plus cGMP deficiencies at its CMO; no safety or efficacy issues were raised.
  • The board decided not to resume internal funding for GTx-102 or GTx-101; it expects USD 9.2 million and USD 4.3 million impairment charges in fiscal 2027 Q1.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-025662), on June 18, 2026, and is solely responsible for the information contained therein.